Evelyn Partners Group Ltd’s Indivior Pharmaceuticals INDV Stock Holding History

Evelyn Partners Group Ltd’s Portfolio INDV Stock Details INDV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$635K	Buy	+15,474	New	+$561K	﹤0.01%	199

Other funds holding INDV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

CAM

Claret Asset Management Montreal, Quebec, Canada $928M AUM 25.4% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

HWAM

Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return

SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return

Evelyn Partners Group Ltd's INDV Position: Q2 2026 in Review

Evelyn Partners Group Ltd opened a new position in Indivior Pharmaceuticals (INDV) in Q2 2026: 15,474 shares worth $635K. The stake represents ﹤0.01% of the portfolio and ranks #199 among its holdings.

125 funds tracked by Wall St. Rank hold INDV as of Q2 2026.

Evelyn Partners Group Ltd held 15,474 shares of Indivior Pharmaceuticals worth $635K as of Q2 2026.
Indivior Pharmaceuticals was a new Evelyn Partners Group Ltd position in Q2 2026.
Indivior Pharmaceuticals made up ﹤0.01% of Evelyn Partners Group Ltd's portfolio in Q2 2026, its #199 holding.
125 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q2 2026.

Based on Evelyn Partners Group Ltd's 13F filing for Q2 2026, filed 7 Aug 2026.